Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial

NCT01752790 is registered in ClinicalTrials.gov with University of Roma La Sapienza as lead sponsor.

NCT NCT01752790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01752790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial
Lead sponsor
University of Roma La Sapienza
Phase
Phase 4
Overall status
Withdrawn
Start date
December 31, 2012
Completion date
December 31, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric crohn's disease